We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Prosecution: Argument for Anti-CTLA-4-based Frontline Combination ICI Treatment of Stage IV Melanoma
Jeffrey S. Weber, MD, PhD
Sapna Patel, MD
Omid Hamid, MD
Jason J. Luke, MD, FACP
Defense: Argument for Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
Ryan Sullivan, MD
Closing Arguments in the Case of Anti-CTLA-4-based Versus Anti-LAG3-based Frontline Combination ICI Treatment of Stage IV Melanoma
How Do We Identify Patients with Localized Prostate Cancer Who Are at Increased Risk for Developing Metastatic Disease?
Rana McKay, MD
Should We Make Active Surveillance More Active for Localized Prostate Cancer?
Neeraj Agarwal, MD, FASCO
What Is the Future of Neoadjuvant ARI Intensification in Localized Prostate Cancer?
Can ARIs Be Combined with Radiation Therapy in High-Risk Localized Prostate Cancer?
How Are ARIs Being Used to Intensify Therapy for High-Risk Localized Prostate Cancer After Local Therapy?
Case Study: How Do We Optimize Treatment Adherence with ARIs in Localized Prostate Cancer?
Expert Panel: What Is the Future of Early Intensification in Localized Prostate Cancer?
Lowering Burden to Raise Adherence: Optimizing Prophylaxis for Hemophilia A
Guy Young, MD
Sickle Cell Disease Across the Life Span: What Your Patients Want You to Know
Biree Andemariam, MD
Caroline Freiermuth, MD
The Burden of Sickle Cell Disease for Patients and Their Families
Diverse Manifestations of Sickle Cell Disease
A Quick Look at Standard Treatments for Sickle Cell Disease
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education